The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.
In one of its partnerships, Gestalt will work to integrate Flagship Bioscience's machine learning tools to enable cancer biomarker detection.
Lantern will use its AI platforms and NCI's omics datasets to identify and validate predictive genomic signatures for drugs it is developing.
The companies will use their respective technologies to identify inhibitors of cancer-associated gene targets and optimize their use as therapeutics.
The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.
The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.
The FDA center of excellence has engaged the technology vendor to incorporate real-world evidence into regulatory decision-making for precision oncology treatments.
Onconova will use Mission Bio's Tapestri platform to study rigosertib — a drug that Onconova is developing — to target the RAS mutation in myelodysplastic syndromes.
The company has signed a new, multiyear agreement with the Korean health system to build a data sharing network to support precision cancer care in East Asia.
The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.